More and more mutations clutter up our DNA as we age. Mostly, these don’t cause problems. But sometimes, a switch will flip, and a mutated cell turns cancerous. Can we see this shift in time to prevent or treat cancer before it starts?
Led by researchers at Fred Hutchinson Cancer Research Center, a scientific team that studies a precancerous condition of the esophagus (called Barrett’s esophagus or BE) are working to answer this question. In work published today in Nature Communications, the team revealed that DNA changes in BE cells that presage esophageal cancer can be spotted years before cancer develops.
The characteristic changes include rearrangements of large chunks of DNA and damage to both copies of a tumor-suppressing gene called TP53.
“Most patients who progressed [to esophageal cancer] had two ‘hits’ [changes that likely inactivate normal gene function] to TP53,” said Dr. Thomas Paulson, a senior staff scientist in the Grady Lab who co-led the project. “In these patients, cells with altered TP53 had spread to larger regions of the esophagus and persisted over longer periods of time compared to patients who didn’t progress to cancer.”
Though the team’s ultimate goal is to improve diagnostics and screening for esophageal cancer, Paulson emphasized that this study compares the mutations and DNA changes that occurred in patients who progressed to cancer with those that occurred in patients with stable, benign BE. While the findings are significant and are based on analysis of over 400 tissue samples, results from this 80-patient study would need to be validated in other patient groups before they could be used clinically to predict whether other BE patients will progress to cancer, he said.
In some people with long-term acid reflux, Barrett’s esophagus arises as a new type of esophageal lining that better resists the damage caused by reflux. Even though it’s often accompanied by DNA mutations, most people will never need treatment for their BE, which will remain benign and stable. But for about 5% of patients with BE, their condition will progress to a kind of cancer called esophageal adenocarcinoma. Though esophageal cancer is relatively rare (about 20,000 new cases are diagnosed each year in the U.S.), it’s aggressive: Only 20% of patients survive five years past diagnosis.
“Once you progress to an advanced esophageal adenocarcinoma, treatment options are quite limited,” Paulson said. “If you can find the tumor when it’s very small, even microscopic, the treatment options are much better.”
However, 95% of patients with BE will never get cancer. For them invasive screening and preventive measures expose them to risks without benefits.
To address this, Fred Hutch’s Dr. Brian Reid and his team set up the Seattle Barrett’s Esophagus Study in the early 1980s. He wanted to learn more about BE, how it progresses, and find any genetic characteristics that flag patients at high or low risk of progressing to cancer.
The ability to sort patients into risk categories, also known as risk stratification, would help doctors give patients the right amount of screening and intervention.
Because the team has studied patients for years, they have a long runway along which they can hunt for clues before cancer takes off.
Previous studies of the genetics of BE and esophageal cancer focused more on changes to specific genes, but now advances in technology allow scientists to understand DNA changes outside genes (where most of our DNA lies). To learn more, the BE team undertook a sequencing study that covers all the DNA in a cell (known as the genome) in 427 tissue samples.
Article continues below.
Learn more about our targeted approach to the diagnosis and treatment of esophageal cancer.
The team looked at small changes that altered just a few letters of DNA, and big changes that added, removed or moved around large swaths of DNA. First, they found that all BE is accompanied by lots of mutations, whether a patient eventually gets cancer or not. The findings also put to rest a hypothesis that BE that precedes cancer develops in a fundamentally different way than BE that remains stable, the researchers said.
“One of the critical results was how many genes were altered in patients who will never go on to cancer, that people think of as cancer-driver genes,” said project co-lead Patty Galipeau, a Public Health Sciences research program manager now in Dr. Gavin Ha’s lab, who helped shepherd the years-long project to completion.
In the researchers’ analyses, one cancer-associated gene in particular, TP53, stood out. It encodes a protein that regulates a lot of important cellular processes, including recognizing damaged DNA, repair and cell growth. It’s one of the most frequently mutated genes in all kinds of cancer — but the team found that some BE patients that didn’t progress to cancer also had a TP53 mutation.
However, their deeper dive into BE DNA revealed that the idea that any TP53 alteration leads to cancer is too simplistic. Humans get two copies of each gene (one from each parent). A person can have a mutation in one copy (one “hit”) or mutations in both copies (two hits).
“Most progressors had two hits in TP53,” said Paulson. Two hits would suggest a person is at very high risk for progressing from BE to cancer, though occasionally a person with one hit may also progress, he said. Patients who progressed to cancer also had TP53 mutations in larger regions of tissue, compared to the single-hit, localized lesions in non-progressing patients.
If both copies of TP53 in a person’s cells are broken, it’s very difficult for them to fix damaged DNA. This leads to duplications, deletions or reshuffling of large pieces of DNA. In fact, the team saw that BE cells in patients who progressed to esophageal cancer were much more likely to contain these large, complex changes than cells from those who never progressed.
Even though the current findings on their own aren’t enough to change diagnostic strategies for patients, the work has important insights that researchers who want to develop a biomarker test should keep in mind, Galipeau said.
“Technology is getting good enough that you can detect TP53 mutations in a very small number of molecules — but that may not be the right way to go,” she said.
As the group’s work shows, finding a single TP53 mutation in just a few cells would be more likely to lump low-risk patients in with high-risk patients, rather than separate them.
Led by senior author Dr. Xiaohong Li, the group is working to integrate these findings with other data, including different types of genetic analyses, to develop an algorithm that can optimize screening times and predict which BE patients are at risk of developing cancer.
Even though Reid retired at the beginning of 2022, research into Barrett’s esophagus using the Barrett’s Esophagus Annotated Repository will continue with Hutch gastroenterologist Dr. Bill Grady taking the helm.
A better future for BE patients will not merely rely on genetic analyses, but on new technologies that make taking biopsies easier or even unnecessary, Galipeau said. With Ha, she, Paulson and the rest of the team are exploring the possibility of developing a screening test based on DNA released from BE cells that would indicate high risk of cancer, which ends up circulating in the blood. (We have a lot of DNA floating in our blood, mostly released from normal cells, and Ha is among the investigators working to develop ways to pinpoint DNA fragment signatures that could help diagnose or monitor cancer.) Such a test would allow doctors to evaluate patient status less invasively, using a blood draw rather than a scope down the throat.
The team also hopes their findings provide insights to other cancer researchers. They think that the genetic changes they spotted may reveal insight into how cells evolve to cope with stressful conditions — and how those coping mechanisms can backfire — and go beyond esophageal-specific cancer mechanisms.
“I think this study emphasizes that when mutations are happening, they’re often happening in a tissue-specific context that’s not specific to cancer itself,” Galipeau said.
The work was funded by the National Institutes of Health.
On April 1, 2022, Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance became Fred Hutchinson Cancer Center, a single, independent, nonprofit organization that is also a clinically integrated part of UW Medicine and UW Medicine’s cancer program. Read more about the restructure.
Are you interested in reprinting or republishing this story? Be our guest! We want to help connect people with the information they need. We just ask that you link back to the original article, preserve the author’s byline and refrain from making edits that alter the original context. Questions? Email us at communications@fredhutch.org
Sabrina Richards, a senior editor and writer at Fred Hutch Cancer Center, has written about scientific research and the environment for The Scientist and OnEarth Magazine. She has a PhD in immunology from the University of Washington, an MA in journalism and an advanced certificate from the Science, Health and Environmental Reporting Program at New York University. Reach her at srichar2@fredhutch.org.
Every dollar counts. Please support lifesaving research today.